Maxim Group initiated coverage on shares of Matinas BioPharma Holdings Inc (NASDAQ:MTNB) in a report issued on Monday. The brokerage set a “buy” rating on the stock.

Separately, Aegis assumed coverage on shares of Matinas BioPharma Holdings in a report on Tuesday, November 1st. They issued a “buy” rating for the company.

Matinas BioPharma Holdings (NASDAQ:MTNB) traded up 0.26% during trading on Monday, hitting $1.54. The company had a trading volume of 25,525 shares. The stock’s market capitalization is $89.39 million. The firm’s 50 day moving average is $1.65 and its 200-day moving average is $0.99. Matinas BioPharma Holdings has a 52-week low of $0.41 and a 52-week high of $2.01.

Matinas BioPharma Holdings Company Profile

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

5 Day Chart for NASDAQ:MTNB

Receive News & Stock Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related stocks with our FREE daily email newsletter.